Business News

    Invex Therapeutics (ASX:IXC) receives regulatory approval for IIH EVOLVE in France

    Article Image

    Australia-based Invex Therapeutics (ASX:IXC) has received French regulatory approval to start its IIH EVOLVE Phase III clinical trial.

    The trial will test the efficacy and safety of Presendin, a once-weekly treatment for neurological conditions caused by raised intracranial pressure.

    The trial will include 240 patients with newly diagnosed Idiopathic Intracranial Hypertension (IIH), which has shown a 350% increase in incidence in the past decade.

    Invex Therapeutics says it plans to open up to 40 clinical sites worldwide for the trial.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa